Ifoxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ifoxetine
Ifoxetine.png
Systematic (IUPAC) name
(3R,4S)-4-(2,3-dimethylphenoxy)piperidin-3-ol
Clinical data
Legal status Uncontrolled
Routes Oral
Identifiers
CAS number 66208-11-5
ATC code None
PubChem CID 71971
ChemSpider 64977
UNII LHH887104B YesY
Chemical data
Formula C13H19NO2 
Mol. mass 221.30 g/mol

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain without affecting it in the periphery.[3] It was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

See also[edit]

References[edit]

  1. ^ Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107. 
  2. ^ Waldmeier PC, Maître L, Baumann PA, et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology 130 (1-2): 1–10. doi:10.1016/0014-2999(86)90177-9. PMID 2877890. 
  3. ^ a b c Delini-Stula A, Fischbach R, Gauthier JM, et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology 2 (3): 201–15. PMID 3320185.